Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.79
-0.0500-1.30%
Post-market: 3.850.0600+1.58%19:30 EDT
Volume:738.90K
Turnover:2.83M
Market Cap:118.59M
PE:-0.92
High:3.91
Open:3.85
Low:3.79
Close:3.84
52wk High:50.40
52wk Low:3.60
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.91
T/O Rate:4.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.54
PE(LYR):-1.33

Loading ...

Pelthos Therapeutics Shareholders Back Directors and Equity Plan

TIPRANKS
·
2 hours ago

Akari Therapeutics Enhances CEO Compensation, Equity Incentives

TIPRANKS
·
2 hours ago

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

GlobeNewswire
·
3 hours ago

Summit Therapeutics is Maintained at Equal-Weight by Barclays

Dow Jones
·
Yesterday

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

GlobeNewswire
·
Yesterday

Akari Therapeutics expands IP portfolio with PCT filing for ADC payload

TIPRANKS
·
Yesterday

Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment

Dow Jones
·
Yesterday

Whitehawk Therapeutics presents real-world analyses of MUC16 in ovarian cancer

TIPRANKS
·
Yesterday

Whitehawk Therapeutics Price Target Announced at $9.00/Share by Stifel

Dow Jones
·
Yesterday

Press Release: HLS Therapeutics Announces Board of Directors Changes

Dow Jones
·
Yesterday

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

GlobeNewswire
·
Yesterday

HC Wainwright Initiates Monte Rosa Therapeutics at Buy With $25 Price Target

MT Newswires Live
·
Yesterday

Stifel Initiates Whitehawk Therapeutics at Buy With $9 Price Target

MT Newswires Live
·
Yesterday

JPMorgan Initiates Spyre Therapeutics at Overweight With $110 Price Target

MT Newswires Live
·
Yesterday

Atossa Therapeutics Price Target Raised to $25.00/Share from $24.00 by Ascendiant Capital

Dow Jones
·
Yesterday

Spyre Therapeutics initiated with an Overweight at JPMorgan

TIPRANKS
·
Yesterday

Neurizon Therapeutics Names CEO; Shares Down 4%

MT Newswires Live
·
Yesterday

Chimeric Therapeutics Suspended as It Negotiates Creditor Deals and Board Restructure

TIPRANKS
·
Yesterday

Have Insiders Sold Cutia Therapeutics Shares Recently?

Simply Wall St.
·
Yesterday

TScan Therapeutics Announces Executive Departures Amid Reorganization

TIPRANKS
·
Yesterday